The latest market report published by Credence Research, Inc. “Global Anti-Hypertensive Drugs Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2023,” the global anti-hypertensive drugs market was valued at USD 32,214.3 Mn in 2015, and is expected to reach USD 34,925.7 Mn by 2023, expanding at a CAGR of 1.2% from 2016 to 2023.
Browse the full report Global Anti-Hypertensive Drugs Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2023 report at http://www.credenceresearch.com/report/anti-hypertensive-drugs-market
Hypertension is commonly observed chronic condition, in which the blood pressure is elevated abnormally both systolic and diastolic. This is major risk factor for causing cardiovascular, renal or endocrine disorder. The normal blood pressure level is 120-140mm Hg systolic and 60-90mm Hg diastolic any elevation above it is considered as hypertension. The major reason for the rise in prevalence of hypertension is lifestyle change, unhealthy food habits and demographic ageing. Anti-hypertensive drugs are used to reduce the level of blood pressure, different drug class of drugs with different mechanism of action exist in the market. The antihypertensive market is growing with increased patient pool especially geriatric population and extensive research and development for novel pipeline drug. The global antihypertensive market show robust growth in forecast period, but it face threat of genericization and increased competition due to patent expiry.
Anti-Hypertensive are categorized by drug class type as Diuretics, Angiotensin receptor blockers (ARBs), Angiotensin converting enzyme (ACE) inhibitors, Beta blockers, Alpha blockers, Calcium channel blockers, Renin inhibitors and Vasodilators. ACE inhibitor occupies the largest market share in terms of value due to mechanism of action and is preferred in geriatric population and diabetes patient as first line of treatment as antihypertensive drug. Beta blockers follow next in line due to preference of physician over diuretic, which are most commonly used.
Based on the drug class type, the global Anti-hypertensive drugs market is segmented as follows:
- ACE inhibitors
- Calcium Channel Blockers
- Beta – Adrenergic blocker
- Alpha – Adrenergic blocker
- Central Sympatholyics
- Renin inhibitors
Click Here To Download Full Report Sample on Anti-Hypertensive Drugs Market : http://www.credenceresearch.com/sample-request/58287
As of the current market scenario, North America is the largest regional market for anti-hypertensive drugs market, followed by the Europe and Asia Pacific. The major factors driving the North America rise in prevalence of hypertension and other associated chronic disease especially in geriatric population, novel drugs in pipeline and upcoming use of combination therapies. Europe major market contributor are UK, Germany, France, Italy and Spain due to factors such as increase in prevalence of hypertension and unmet need for treatment of chronic disease, health care program planning and expenditure. Asia-Pacific is the fastest growing market due to rise population and incidence of chronic diseases due to alteration in lifestyle changes; and health care infrastructure and government expenditure. Thus developed market dominates the antihypertensive drugs market, with developing economies booming at fast rate.
Market Competition Assessment:
Key players in the global Anti-Hypertensive drugs market are
Novartis AG, Astra Zeneca, Pfizer Inc., Acetelion Ltd, Sanofi S.A., Merck & Co., Boehringer Ingelheim, Lupin Limited, Johnson & Johnson Ltd., Astra Zeneca Plc, Daiichi Sankyo Company Limited and Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceutical, Bayer AG etc.
Key Market Movements:
- Rising prevalence of hypertension due to various factors such as growing population, change in unhealthy lifestyle etc.
- Extensive R&D for new treatment regimen and new drug approval in pipeline
- Evolving use of combination therapy to lower the blood pressure and decrease in adverse effect